Search results
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
Zacks via Yahoo Finance· 12 hours agoFDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use...
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 4 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 3 days agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
Vanguard Group Inc. Acquires 6,572 Shares of Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 4 days agoVanguard Group Inc. boosted its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 0.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission ...
Cardinal Capital Management Inc. Sells 3,561 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 10 hours agoCardinal Capital Management Inc. cut its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 1.8% during the 1st quarter, according to the company in its most recent Form 13F filing ...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 2 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 2 days agoThis approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S., including psoriatic arthritis,
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
Morningstar· 1 day agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 3 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND2Data showed that clinical remission,